Register
Login:
Share:
Email Facebook Twitter


Tech company Mporium delivers an outstanding set of Q1 results says CEO De Groot
IronRidge Resources CEO hails spectacular lithium project and money making potential for gold




Share Price Information for Valirx (VAL)


Share Price: 0.525Bid: 0.50Ask: 0.55Change: 0.00 (0.00%)No Movement on Valirx
Spread: 0.05Spread as %: 10.00%Open: 0.55High: 0.00Low: 0.00Yesterday’s Close: 0.525

Valirx Plc Ord 0.1P

Valirx is listed in the FTSE AIM All-Share
Valirx is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
0.525
Share Price SpacerBid
0.50
Share Price SpacerAsk
0.55
Share Price SpacerChange
0%0.00
Share Price SpacerVolume
0
Share Price SpacerOpen
0.55
Share Price SpacerHigh
0.00
Share Price SpacerLow
0.00
Share Price SpacerClose
0.525
Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 681.63m £3.58m 150,000

52 Week High 4.13 52 Week High Date 30-APR-2018
52 Week Low 0.49 52 Week Low Date 20-MAR-2019

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
0 0 0 -0.276 -1.90 0.00 0.00


London South East Users info for Valirx




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

18-Apr-19
16:27:19
0.535
91,775
Buy* 
0.50
0.55
491.00
Trade Type:
Ordinary

18-Apr-19
16:11:05
0.552
878,678
Buy* 
0.50
0.55
4,850
Trade Type:
Ordinary
NonProtected portfolio
Single protected transaction

18-Apr-19
15:37:03
0.511
12,670
Sell* 
0.50
0.55
64.74
Trade Type:
Ordinary




View more Valirx trades >>

Directors Deals for Valirx (VAL)
Trade DateActionNotifierPriceCurrencyAmountHolding
18-Dec-18Placing
Trade Notifier Information for Valirx
Satu Vainikka held the position of CEO at Valirx at the time of this trade.
 Satu Vainikka
0.75GBX1,333,3331958242
18-Dec-18Placing
Trade Notifier Information for Valirx
George Morris held the position of Non-Executive Director at Valirx at the time of this trade.
 George Morris
0.75GBX1,333,3331821620
18-Dec-18Placing
Trade Notifier Information for Valirx
Alexander Oliver de Giorgio-Miller held the position of Non-Executive Chairman at Valirx at the time of this trade.
 Alexander Oliver de Giorgio-Miller
0.75GBX1,333,3331392888
View more Valirx directors dealings >>


Noise
Posts: 3,043
Opinion:No Opinion
Price:0.525
RE: From Here AIMOO
Today 13:50
CAR-T should be available for late stage cancers within 5 years, assuming no big surprises. I'm not sure it'll be the best first-time treatment option for hormonally driven cancers, androgen blockers, surgery and potentially val201 would strike me as better options. Val101/bcl2 regulators could be interesting, but alas I have no idea wth is going on with val101, it is a complicated compound and I guess Val haven't quite had the funds to push it much recently.
nomlungu
Posts: 2,908
Opinion:No Opinion
Price:0.525
RE: From Here AIMOO
Today 12:24
I Spy,

I do not view VAL201 as 'old hat'. Funding for further trials of the drug will have been hampered by the hype around CAR-T therapies but that hype has died down and the share prices of many immunotherapy drug discovery companies have slumped, and with that the funding that could have gone towards their trials is more likely to be available trials by companies such as Valirx.

CAR-T therapies have had limited success treating solid tumors - any drug that can slow tumour growth and reduce metastasis (which is what the VAL201 trial is attempting to prove) would be well received by the market.

My post was just a response to the post about a 20 bagger from VAL201 and wondering if there was some research that I was missing.

Despite what some may think, I would like to see progress with Valirx's compounds for both Cancer sufferers as well as the shareholders. I may well end up buying shares here again once funding is clearer.
Uncanny
Posts: 1,358
Opinion:No Opinion
Price:0.525
RE: From Here AIMOO
Today 10:34
Noise
CAR-T is a decade away as you say.
Why do you think we suffer the daily barrage of de-ramping attackers on here and ADVFN?
Because VAL’s compounds are a serious threat to various other small bios products because VAL are so close to commercialisation and this gives them brown underpants.
LOL
Hoping for more LoI for 401and extremely excited at the next 201 update.
Noise
Posts: 3,043
Opinion:No Opinion
Price:0.525
RE: From Here AIMOO
Today 10:09
I see CAR-T as a later stage treatment for the next 5 years or so. Autolus have some interesting trials with fast off switching that could improve industry confidence with it (historic trials with CAR-T solutions included some serious side effects).

I think nomlungu may be academically correct with the protein Vs peptide argument, but it would still have to progress through pre-clinical studies and I'm not aware of a protein version of 201, so that would take 5-10 years of playing catch up?
IsleworthSpy
Posts: 688
Opinion:No Opinion
Price:0.525
RE: From Here AIMOO
Sun 17:51
@ nomlungo.

For clarity: Are you saying that 201 is old hat? That there is no place in the market, despite the apparent developmental success, as released in recent RNS's?

Excellent links by the way. But it would seem that CAR T therapy is not a one cure for all cancers.
All IMO by the way, as a humble postie. And I do stand to be corrected.

I Spy
View more share chat for Valirx (VAL) >>







Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk











Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.